Trouble falling asleep and waking repeatedly during the night are both sleep problems. When reading a medicine's approved indication, that distinction matters.
Rozerem S, a ramelteon product sold in Japan under pharmacist guidance, is approved for temporary difficulty falling asleep. The original application also included light sleep. During the review, the applicant was asked to align the proposed indication with that of prescription Rozerem and narrowed it to difficulty falling asleep.
What, then, did the trials measure about sleep after people had fallen asleep?
Ministry committee minutes (Japanese) · Product information (Japanese)